4.7 Review

Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects

期刊

NEUROIMAGE
卷 48, 期 4, 页码 668-681

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.neuroimage.2009.07.011

关键词

-

资金

  1. NIH [U01 AG024904]
  2. National Institute of Aging
  3. National Institute of Biomedical Imaging and Bioengineering (NIBIB)
  4. Foundation for the National Institutes of Health
  5. Pfizer Inc.
  6. Wyeth Research
  7. Bristol-Myers Squibb
  8. Eli Lilly and Company
  9. GlaxoSmithKline
  10. Merck and Co. Inc.
  11. AstraZeneca AB
  12. Novartis Pharmaceuticals Corporation
  13. Alzheimer's Association
  14. Eisai Global Clinical Development
  15. Elan Corporation plc
  16. Forest Laboratories
  17. Institute for the Study of Aging (ISOA)
  18. Northern California Institute for Research and Education
  19. University of California, San Diego
  20. National Library of Medicine
  21. National Center for Research Resources [AG016570, EB01651, LM05639, RR019771]

向作者/读者索取更多资源

Tensor-based morphometry (TBM) is a powerful method to map the 3D pro. le of brain degeneration in Alzheimer's disease (AD) and mild cognitive impairment (MCI). We optimized a TBM-based image analysis method to determine what methodological factors, and which image-derived measures, maximize statistical power to track brain change. 3D maps, tracking rates of structural atrophy over time, were created from 1030 longitudinal brain MRI scans (1-year follow-up) of 104 AD patients (age: 75.7 +/- 7.2 years; MMSE: 23.3 +/- 1.8, at baseline), 254 amnestic MCI subjects (75.0 +/- 7.2 years; 27.0 +/- 1.8), and 157 healthy elderly subjects (75.9 +/- 5.1 years; 29.1 +/- 1.0), as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI). To determine which TBM designs gave greatest statistical power, we compared different linear and nonlinear registration parameters (including different regularization functions), and different numerical summary measures derived from the maps. Detection power was greatly enhanced by summarizing changes in a statistically-defined region-of-interest (ROI) derived from an independent training sample of 22 AD patients. Effect sizes were compared using cumulative distribution function (CDF) plots and false discovery rate methods. In power analyses, the best method required only 48 AD and 88 MCI subjects to give 80% power to detect a 25% reduction in the mean annual change using a two-sided test (at alpha=0.05). This is a drastic sample size reduction relative to using clinical scores as outcome measures (619 AD/6797 MCI for the ADAS-Cog, and 408 AD/796 MCI for the Clinical Dementia Rating sum-of-boxes scores). TBM offers high statistical power to track brain changes in large, multi-site neuroimaging studies and clinical trials of AD. (C) 2009 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据